Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects.

Papasavvas E, Azzoni L, Kossenkov AV, Dawany N, Morales KH, Fair M, Ross BN, Lynn K, Mackiewicz A, Mounzer K, Tebas P, Jacobson JM, Kostman JR, Showe L, Montaner LJ.

J Immunol. 2019 Aug 1;203(3):705-717. doi: 10.4049/jimmunol.1801511. Epub 2019 Jun 28.

PMID:
31253727
2.

Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.

Lo Re V 3rd, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN; North American AIDS Cohort Collaboration on Research and Design of IeDEA.

J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):71-80. doi: 10.1097/QAI.0000000000002094.

PMID:
31107304
3.

Listen to Your Heart.

Kostman JR.

JAMA. 2019 May 14;321(18):1769-1770. doi: 10.1001/jama.2019.5165. No abstract available.

PMID:
31087026
4.

Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people.

Torgersen J, So-Armah K, Freiberg MS, Goetz MB, Budoff MJ, Lim JK, Taddei T, Butt AA, Rodriguez-Barradas MC, Justice AC, Kostman JR, Lo Re V 3rd.

BMC Gastroenterol. 2019 Apr 15;19(1):52. doi: 10.1186/s12876-019-0969-1.

5.

Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV.

Papasavvas E, Lada SM, Joseph J, Yin X, Liu Q, Azzoni L, Mounzer K, Kostman JR, Richman D, Montaner LJ.

AIDS. 2018 Aug 24;32(13):1763-1772. doi: 10.1097/QAD.0000000000001909.

6.

Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.

Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick P, Lo Re V 3rd.

Open Forum Infect Dis. 2018 Jun 7;5(6):ofy076. doi: 10.1093/ofid/ofy076. eCollection 2018 Jun.

7.

Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.

Byrne DD, Tate JP, Forde KA, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Bedimo R, Freiberg MS, Justice AC, Kostman JR, Roy JA, Lo Re V 3rd.

Clin Infect Dis. 2017 Oct 16;65(9):1542-1550. doi: 10.1093/cid/cix564.

8.

Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.

Lo Re V Rd, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA.

Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1172-1181. doi: 10.1002/pds.4258. Epub 2017 Jul 19.

9.

Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.

Gowda C, Newcomb CW, Liu Q, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Roy JA, Marks AR, Schneider JL, Kostman JR, Tate JP, Lim JK, Justice AC, Goetz MB, Corley DA, Lo Re V.

Open Forum Infect Dis. 2017 Jan 28;4(2):ofx012. doi: 10.1093/ofid/ofx012. eCollection 2017 Spring.

10.

HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.

Papasavvas E, Azzoni L, Yin X, Liu Q, Joseph J, Mackiewicz A, Ross B, Lynn KM, Jacobson JM, Mounzer K, Kostman JR, Montaner LJ.

J Viral Hepat. 2017 Oct;24(10):865-876. doi: 10.1111/jvh.12714. Epub 2017 May 11.

11.

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1035-43. doi: 10.1016/j.cgh.2016.03.040. Epub 2016 Apr 5.

12.

Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients.

Lo Re V 3rd, Kallan MJ, Tate JP, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park LS, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR.

Open Forum Infect Dis. 2015 Jul 9;2(3):ofv109. doi: 10.1093/ofid/ofv109. eCollection 2015 Sep.

13.

Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.

Trooskin SB, Reynolds H, Kostman JR.

Clin Infect Dis. 2015 Dec 15;61(12):1825-30. doi: 10.1093/cid/civ677. Epub 2015 Aug 12. Review.

PMID:
26270682
14.

Correction for Patro et al., Shift in Monocyte Apoptosis with Increasing Viral Load and Change in Apoptosis-Related ISG/Bcl2 Family Gene Expression in Chronically HIV-1-Infected Subjects.

Patro SC, Pal S, Bi Y, Lynn K, Mounzer KC, Kostman JR, Davuluri RV, Montaner LJ.

J Virol. 2015 Jul;89(13):6970. doi: 10.1128/JVI.00735-15. No abstract available.

15.

Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection.

Ogdie A, Pang WG, Forde KA, Samir BD, Mulugeta L, Chang KM, Kaplan DE, Amorosa VK, Kostman JR, Reddy RK, Schumacher RH, Lo Re V 3rd.

BMC Musculoskelet Disord. 2015 Apr 19;16:93. doi: 10.1186/s12891-015-0552-z.

16.

Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women.

Lo Re V 3rd, Lynn K, Stumm ER, Long J, Nezamzadeh MS, Baker JF, Hoofnagle AN, Kapalko AJ, Mounzer K, Zemel BS, Tebas P, Kostman JR, Leonard MB.

J Infect Dis. 2015 Sep 15;212(6):924-33. doi: 10.1093/infdis/jiv147. Epub 2015 Mar 9.

17.

Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KB, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd.

J Viral Hepat. 2015 Nov;22(11):936-47. doi: 10.1111/jvh.12398. Epub 2015 Mar 6.

18.

Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Papasavvas E, Foulkes A, Yin X, Joseph J, Ross B, Azzoni L, Kostman JR, Mounzer K, Shull J, Montaner LJ.

Immunology. 2015 Jul;145(3):380-90. doi: 10.1111/imm.12452. Epub 2015 May 19.

19.

Shift in monocyte apoptosis with increasing viral load and change in apoptosis-related ISG/Bcl2 family gene expression in chronically HIV-1-infected subjects.

Patro SC, Pal S, Bi Y, Lynn K, Mounzer KC, Kostman JR, Davuluri RV, Montaner LJ.

J Virol. 2015 Jan;89(1):799-810. doi: 10.1128/JVI.02382-14. Epub 2014 Oct 29. Erratum in: J Virol. 2015 Jul;89(13):6970.

20.

A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers.

Tomescu C, Liu Q, Ross BN, Yin X, Lynn K, Mounzer KC, Kostman JR, Montaner LJ.

PLoS One. 2014 Jul 31;9(7):e103209. doi: 10.1371/journal.pone.0103209. eCollection 2014.

21.

Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.

Lo Re V 3rd, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC.

Ann Intern Med. 2014 Mar 18;160(6):369-79. doi: 10.7326/M13-1829.

22.

Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KB, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd.

J Hepatol. 2014 Aug;61(2):210-8. doi: 10.1016/j.jhep.2014.04.001. Epub 2014 Apr 5.

23.

Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000-2007.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KB, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio R, Lo Re V 3rd.

Ann Epidemiol. 2014 Jun;24(6):418-23. doi: 10.1016/j.annepidem.2014.02.013. Epub 2014 Mar 5.

24.

Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.

Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd.

J Viral Hepat. 2014 Apr;21(4):288-96. doi: 10.1111/jvh.12142. Epub 2013 Jul 30.

25.

Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients.

Amorosa VK, Aibana O, Shire NJ, Dorey-Stein Z, Ferrara T, Gilmore J, Kostman JR, Lo Re V 3rd.

J Clin Gastroenterol. 2013 May-Jun;47(5):457-60. doi: 10.1097/MCG.0b013e318266fe70.

26.

Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection.

Lo Re V 3rd, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman JR, Tebas P, Leonard MB, Localio AR.

Hepatology. 2012 Nov;56(5):1688-98. doi: 10.1002/hep.25866. Epub 2012 Oct 14.

27.

Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects.

Papasavvas E, Chehimi J, Azzoni L, Pistilli M, Thiel B, Mackiewicz A, Creer S, Mounzer K, Kostman JR, Montaner LJ.

AIDS Res Hum Retroviruses. 2010 Oct;26(10):1047-9. doi: 10.1089/aid.2010.0020. Epub 2010 Aug 18. No abstract available.

28.

Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients.

DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re V 3rd.

BMC Infect Dis. 2010 May 13;10:116. doi: 10.1186/1471-2334-10-116.

29.

The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients.

Amorosa VK, Slim J, Mounzer K, Bruno C, Hoffman-Terry M, Dorey-Stein Z, Ferrara T, Kostman JR, Lo Re V 3rd.

Antivir Ther. 2010;15(1):91-9. doi: 10.3851/IMP1492.

30.

HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.

Goetz MB, Leduc R, Wyman N, Kostman JR, Labriola AM, Lie Y, Weidler J, Coakley E, Bates M, Luskin-Hawk R; Long Term Monitoring Study (CPCRA060) Terry Beirn Community Programs for Clinical Research on AIDS.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):472-9. doi: 10.1097/QAI.0b013e3181cae480.

31.

Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men.

Lo Re V 3rd, Guaraldi G, Leonard MB, Localio AR, Lin J, Orlando G, Zirilli L, Rochira V, Kostman JR, Tebas P.

AIDS. 2009 Oct 23;23(16):2191-8. doi: 10.1097/QAD.0b013e32832ec258.

32.

Evidence of a decrease in CD4 recovery once back on antiretroviral therapy after sequential > or =6 weeks antiretroviral therapy interruptions.

Papasavvas E, Foulkes A, Li X, Kostman JR, Mounzer KC, Montaner LJ.

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):334-5. doi: 10.1097/QAI.0b013e3181966b0c. No abstract available.

33.

Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection.

Goetz MB, Leduc R, Kostman JR, Labriola AM, Lie Y, Weidler J, Coakley E, Bates M, Luskin-Hawk R; Long-Term Monitoring Study (CPCRA 060) and Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):259-66. doi: 10.1097/QAI.0b013e3181989a8b. Erratum in: J Acquir Immune Defic Syndr. 2009 May 1;51(1):110.

34.

Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.

Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J, Janmey PA, DiNubile MJ, Ondercin J, Kostman JR, Mounzer KC, Montaner LJ.

AIDS. 2009 Jan 28;23(3):369-75. doi: 10.1097/QAD.0b013e32831e9c76.

35.

Adherence to hepatitis C virus therapy and early virologic outcomes.

Lo Re V 3rd, Amorosa VK, Localio AR, O'Flynn R, Teal V, Dorey-Stein Z, Kostman JR, Gross R.

Clin Infect Dis. 2009 Jan 15;48(2):186-93. doi: 10.1086/595685.

36.

HIV type 1 viremia on ART is positively associated with polyclonal T cell proliferation in subjects with T cell IFN-gamma secretion levels comparable to those of uninfected subjects.

Papasavvas E, Moore EC, Sun J, Azzoni L, Pistilli M, Mounzer K, Shull J, Kostman JR, Montaner LJ.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1203-8. doi: 10.1089/aid.2008.0054.

37.

Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century.

Lo Re V 3rd, Kostman JR, Amorosa VK.

Clin Liver Dis. 2008 Aug;12(3):587-609, ix. doi: 10.1016/j.cld.2008.03.009. Review.

38.
39.

Incidence of transaminitis among HIV-infected patients with occult hepatitis B.

Lo Re V 3rd, Wertheimer B, Localio AR, Kostman JR, Dockter J, Linnen JM, Giachetti C, Dorey-Stein Z, Frank I, Strom BL, Gross R.

J Clin Virol. 2008 Sep;43(1):32-6. doi: 10.1016/j.jcv.2008.03.030. Epub 2008 May 16.

40.

Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.

Dorey-Stein Z, Amorosa VK, Kostman JR, Lo Re V 3rd, Shannon RP.

J Cardiometab Syndr. 2008 Spring;3(2):111-4. No abstract available.

41.

Self-reported hepatitis B and C virus infections had low sensitivity among HIV-infected patients.

Lo Re V 3rd, Frank I, Gross R, Synnestvedt M, Localio AR, Kostman JR, Strom BL.

J Clin Epidemiol. 2007 Mar;60(3):294-9. Epub 2006 Nov 13.

PMID:
17292024
42.

Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy.

Lo Re V 3rd, Kostman JR, Gross R, Reddy KR, Mounzer K, Zemel BS, Rennert H, Stieritz DD, Putt M, Frank I, Strom BL.

J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):344-50.

PMID:
17179767
43.

Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients.

Lo Re V 3rd, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, Tebas P, Stern J, Synnestvedt M, Localio AR, Kostman JR, Strom BL.

J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):315-20.

PMID:
17159655
44.

Obstructive sleep apnoea among HIV patients.

Lo Re V 3rd, Schutte-Rodin S, Kostman JR.

Int J STD AIDS. 2006 Sep;17(9):614-20.

PMID:
16942653
45.

HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption.

Papasavvas E, Kostman JR, Thiel B, Pistilli M, Mackiewicz A, Foulkes A, Gross R, Jordan KA, Nixon DF, Grant R, Poulin JF, McCune JM, Mounzer K, Montaner LJ.

J Clin Immunol. 2006 Jan;26(1):40-54.

PMID:
16418802
46.

Effect of GB virus C viremia on HIV acquisition and HIV set-point.

Bisson GP, Strom BL, Gross R, Weissman D, Klinzman D, Hwang WT, Kostman JR, Metzger D, Stapleton JT, Frank I.

AIDS. 2005 Nov 4;19(16):1910-2.

PMID:
16227800
47.

IL-13 acutely augments HIV-specific and recall responses from HIV-1-infected subjects in vitro by modulating monocytes.

Papasavvas E, Sun J, Luo Q, Moore EC, Thiel B, MacGregor RR, Minty A, Mounzer K, Kostman JR, Montaner LJ.

J Immunol. 2005 Oct 15;175(8):5532-40.

48.

Management of chronic hepatitis C.

Lo Re V 3rd, Kostman JR.

Postgrad Med J. 2005 Jun;81(956):376-82. Review.

49.

Seronegative secondary syphilis in 2 patients coinfected with human immunodeficiency virus.

Kingston AA, Vujevich J, Shapiro M, Hivnor CM, Jukic DM, Junkins-Hopkins JM, Jih DM, Kostman JR, James WD.

Arch Dermatol. 2005 Apr;141(4):431-3. No abstract available.

PMID:
15837859
50.

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ.

PLoS Med. 2004 Dec;1(3):e64. Epub 2004 Dec 28.

Supplemental Content

Loading ...
Support Center